Thanks Hottod, you are a goldmine of quality data points - current and historical
I guess we are still early, but how does PYC (pre-Clinical) discovery process/data points compare?
Been impressed by the process/data for VP-001 superior at that time, but have noticed industry catching up to soon making it the norm.
I share fellow HC’s bias to market not appreciating quantitative of PYC pre-clinical methodology hence making our beloved company seriously undervalued.
If PYC can somehow demonstrate capabilities to replicate our VP-001 discovery process to deliver multiple lead candidates across indications/modalities (as per AGM preso) then I guess the market (and industry) will make PYC more desirable.
Today we rest on VP-001 being our singular arrow, by end of ‘22 we should have a quiver full of them, with targets beyond rare ocular IRD indications…. I never quite liked statins:
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)